ACEMANNAN INCORPORATION INTO NANOSTRUCTURE LIPID CARRIER FOR RIFAMPICIN DELIVERY SYSTEM
Mycobacterium tuberculosis (Mtb) is a pathogen that has ability to survive without infection symptom as latent phase of tuberculosis. During this infection, lipoarabinomannan present on Mtb surfaces cause a decrease in the immune response. This research aims. to develop rifampicin delivery systems a...
Saved in:
| Main Author: | |
|---|---|
| Format: | Final Project |
| Language: | Indonesia |
| Online Access: | https://digilib.itb.ac.id/gdl/view/79005 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | Mycobacterium tuberculosis (Mtb) is a pathogen that has ability to survive without infection symptom as latent phase of tuberculosis. During this infection, lipoarabinomannan present on Mtb surfaces cause a decrease in the immune response. This research aims. to develop rifampicin delivery systems as antituberculosis that contains acemannan as immunostimulant. It is known that acemannan, the major polysaccharide in Aloe vera, has immunomodulatory activity through activation of macrophages. Nanostructure lipid carrier was prepared by emulsificationultrasonication technique with low temperatuR solidification. Nanostructure lipid carrier consisted of oleic acid, suppocire NA and cetostearyl alcohol as lipid phase. Rifampicin was dissolved into lipid phase of nanostructure tipid carrier that was stabilized by polysorbate 80 and polyethylene glycol 400 as surfactant and cosurfactant respectively. Nanostructure lipid carrier was developed further by adding a dispersion of acemannan in oleic acid. The dispersion of acemannan was prepared by emulsification and lyophilization technique. Nanostructure lipid carrier was evaluated by measuring particle size, polydispersity index, potential zeta, and entrapment emciency of rifampicin. The optimum formula comprised of the oil phase as mixture of oleic acid, suppociæ NA and cetostearyl alcohol in the ratio of 1: l: 2, polysorbate 80 and PEG 400 in ratio of 4 : 3 and 0.08% of acemannan dispersion in oil. The loading of acemannan did not alter particle size of nanostructure lipid carrier was 128.9 ± 6.14 nm (p>0.05), polydispersity index was 0.34 ± 0.021, potential zeta was -4.13 mV. The entrapment efficiency of rifampicin in nanostructure lipid carrier was 76.07 ± 2.5 %. In conclusion, the optimum formula of acemannan loaded into nanostructure lipid carrier was obtained with the expected specification. This formula is promising be to develop for tuberculosis treatment.
|
|---|